Evidence map›Paper›PMID 42889389›Full record

Trial reportFrontiers in systems neuroscience2026

Pharmacologically altered androgens, brain activation and response inhibition in a stop-signal task in male heavy drinkers.

Marlene Kundlacz, Rafat Boroumand-Jazi, Sabine Hoffmann, Christiane Mühle, Iris Reinhard, Matthias Reichl, Leonard Wenger, Haoye Tan, Patrick Bach, Sabine Vollstädt-Klein and 4 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in systems neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marlene KundlaczDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Rafat Boroumand-JaziDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Sabine HoffmannDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Christiane MühleDepartment of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich- Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Iris ReinhardCore Facility Biostatistics, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Matthias ReichlDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Leonard WengerDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Haoye TanDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Patrick BachDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Sabine Vollstädt-KleinDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Georg W AlpersOtto Selz Institute and Department of Psychology, School of Social Sciences, University of Mannheim, Mannheim, Germany.
Falk KieferDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Bernd Lenz *Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Sarah Gerhardt *Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heavy episodic drinking (HED) is highly prevalent in men and a major risk factor for Alcohol Use Disorder (AUD). Previous studies indicated an influence of testosterone (T) on AUD, and dihydrotestosterone (DHT) was linked to alcohol consumption, impulsivity, and response inhibition. As the role of androgens in AUD and the modulation thereof is not fully understood, this study investigated the effect of a pharmacological reduction in DHT by inhibition of the 5-alpha reductase II with finasteride on brain activation and response inhibition during a stop signal task. Fifty males with HED participated in a randomized, placebo-controlled, double blind, cross-over, functional magnetic resonance imaging (fMRI) study. Participants received either 5 mg finasteride or placebo, resulting in a 9.6% reduction of DHT levels. Full factorial fMRI models and linear mixed models were used to estimate whole-brain effects of DHT and testosterone following finasteride and placebo on neural correlates of behavioral control ( Clinical trial registration: https://drks.de/search/de/trial/DRKS00020569, identifier DRKS00020569.

Indexed as

alcoholDHTinhibitory controlneuroimagingtestosterone

Identifiers

PMID42889389
PMCPMC13669173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.